Rogerio Vivaldi jumps from Bioverativ buyout to leading Flagship-seeded Sigilon's Holy Grail pursuit
Back in April, Sigilon CEO Paul Wotton told me that the $473 million deal he had struck with Eli Lilly helped highlight the upstart …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
